The stock of DBV Technologies S.A. (DBVT) lost 20.00% in the pre-market to $1.40 after releasing the fiscal performance for FY2021. DBVT stock closed the regular trading session at $1.75, gaining 34.62% from the previous day’s trading session. The stock kept moving between $1.44 and $1.75. DBV Technologies also filed form 8-K with the SEC on 3 March 2022.
DBV Technologies SA is a biopharmaceutical firm known for creating “Viaskin” innovation. It regulates the allergens or antigens to unblemished skin while keeping away from any movement to the blood. The company has a market cap of $96.14 million with 54.94 million pending shares. DBVT has its headquarter in Mont rouge, France.
DBVT’s key financials
On 3 March 2022, DBV Technologies released the fiscal performance for FY2021. The firm’s sales for FY21 reduced by 49.3% to $5.7 million in 2021 from $11.2 million in 2020. DBVT had the expense from the operation of $104.3 million in 2021 versus $170.1 million in 2020. This marks a contraction of 38.6% in the expenses from operations. Moreover, the firm reported a total loss of $97.8 million in 2021 against $159.5 million in 2020. The total loss declined by 38.6%. Also, the loss of $1.78 per stock in 2021 is compared to the loss of $2.95 per stock in 2020. The loss per stock also declined by 39.6%. Moreover, as of December 31, 2021, DBVT had total assets worth $146.7 million of which cash and cash equivalents were $77.3 million.
CEO Remarks
The CEO of DBVT, Daniel Tasse, commented that starting the new Phase 3 preliminary with the mVP is their main concern. They are satisfied with the continuous discussions with FDA. He further added that they expect this financial position will give DBV an adequate chance to acquire an alliance with FDA on the convention for the mVP essential preliminary.
Further, Mr. Tasse concluded that they expect to understand the maximum capacity of the Viaskin innovation for patients and families.
